Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
An NCI-sponsored trial characterizes individuals and families at high risk of hematologic cancers, focusing on conditions including Waldenst…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) [Phase 2]
This document provides an update on a Phase 2 clinical trial evaluating the combination of mosunetuzumab with pirtobrutinib in patients with…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies [Phase 1, Phase 2]
This is a Phase 1/2 dose-escalation and expansion study of BGB-16673 in patients with various B-cell malignancies and is currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers [Phase 1]
This document outlines an ongoing Phase 1 trial evaluating NKX019, an allogeneic CAR NK cell therapy, in adults with B-cell cancers includin…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
This observational study investigates cardiac arrhythmias in patients treated with BTK inhibitors or venetoclax in chronic lymphocytic leuke…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial update for BGB-16673, a BTK-targeted protein degrader, in Chinese participants with various B-cell malignan…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies [Phase 2]
Phase 2 study evaluating a two-step reduced-intensity conditioning approach for bone marrow transplant in adults with hematologic malignanci…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
NX-5948 is being studied in a Phase 1 trial for adults with relapsed/refractory B-cell malignancies; the study is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: SynKIR-310 for Relapsed/Refractory B-NHL [Phase 1]
Phase 1 trial update for SynKIR-310 in relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
This clinical trial status update indicates an ongoing natural history study of Monoclonal B-Cell Lymphocytosis, chronic lymphocytic leukemi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) [Phase 2]
A Phase 2 trial evaluating oral venetoclax in adults with relapsed or refractory Waldenström macroglobulinemia and lymphoplasmacytic lymphom…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) [Phase 2]
Phase 2 trial update on the efficacy and safety of Nemtabrutinib (MK-1026) in hematologic malignancies, including Waldenström macroglobuline…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Long-term Extension Study of PCI-32765 (Ibrutinib) [Phase 3]
Phase 3 long-term extension study of ibrutinib (PCI-32765) in chronic lymphocytic leukemia/small lymphocytic lymphoma and other B-cell malig…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma [Phase 2]
An ongoing Phase 2 clinical trial compares the combination of venetoclax and rituximab against the usual treatment (ibrutinib plus rituximab…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T [Phase 1]
This clinical trial update reports long-term follow-up results from a Phase 1 study of CLBR001 CAR-T cells in relapsed/refractory B-cell lym…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM [Phase 2]
A Phase 2 trial evaluating Zanubrutinib, Bendamustine, and Rituximab in previously untreated Waldenström macroglobulinemia is currently recr…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
A clinical trial registry update from Dana-Farber Cancer Institute notes a study involving questionnaires and tissue banking for multiple my…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial evaluating Sonrotoclax (BGB-11417), a Bcl-2 inhibitor, in participants with mature B-cell malignancies. The study is …
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 clinical trial evaluating Rituximab plus Bendamustine and ibrutinib (PCI-32765) in relapsed DLBCL, mantle cell lymphoma, and various…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
Phase 1 study evaluating NX-2127 in adults with relapsed or refractory B-cell malignancies; currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom [Phase 2]
Phase 2 clinical trial update for CLR-131 in select B-cell malignancies, with expansion into Waldenström macroglobulinemia. The study status…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. [Phase 4]
BLOOD-dose is a Phase 4 platform trial evaluating dose optimization in hematologic diseases, with Waldenström macroglobulinemia and multiple…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Phenotypic and Functional Study of Bone Marrow Mesenchymal Stem Cells in Waldenström Macroglobulinemia [NA]
This clinical trial studies the phenotypic and functional characteristics of bone marrow mesenchymal stem cells in Waldenström macroglobulin…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Epcoritamab in Previously Treated WM [Phase 2]
Epcoritamab is being studied in a Phase 2 trial for patients with Waldenström macroglobulinemia who have received prior treatment; the study…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Lisaftoclax (APG-2575) as a monotherapy in indolent lymphomas, including Waldenström mac…